Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
intradigm.com

See what CB Insights has to offer

Founded Year

2000

Stage

Merger | Merged

Total Raised

$38.75M

About Intradigm Corporation

Intradigm is a private biotechnology company focused on the discovery, development and delivery of novel targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses a comprehensive RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. Intradigm and its partners have several products in clinical development.

Intradigm Corporation Headquarter Location

3350 West Bayshore Road Suite 100

Palo Alto, California, 94303,

United States

650-855-9696

Latest Intradigm Corporation News

Silence and Intradigm merge RNAi forces, flag deals - FierceBiotech

Jun 19, 2013

Reprint Two small RNAi players are merging forces in hopes of attracting some increased attention from the Big Pharma coaches calling the partnership plays. The UK's Silence Therapeutics  will issue $26 million in shares to acquire Palo Alto, CA-based Intradigm , giving Intradigm's shareholders a 36.6 percent slice of the combined pie. Silence also says that it raised £15 million from a share placement while a group of investors including Alta Partners, Frazier Healthcare, Lilly Ventures, Roche Finance and Astellas Venture chipped in five million pounds. After the merger goes through, Intradigm CEO Philip Haworth becomes CEO of the combined venture while Silence Chairman Iain Ross stays on in the same post. "By bringing together a comprehensive platform of siRNA delivery and development technologies, we believe Silence Therapeutics will be a partner of choice for those seeking to develop RNAi therapeutics," said Ross. "With a strengthened balance sheet, experienced management and extended research capability, Silence Therapeutics is well placed to strike the development deals that will deliver value for shareholders. " - here's the  release for more info - check out the story from Reuters Related Articles:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Intradigm Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intradigm Corporation is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Intradigm Corporation Patents

Intradigm Corporation has filed 6 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/29/2007

2/22/2011

Experimental cancer drugs, Monoclonal antibodies, Immunology, Clusters of differentiation, Immune system

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/29/2007

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/22/2011

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Experimental cancer drugs, Monoclonal antibodies, Immunology, Clusters of differentiation, Immune system

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.